Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed glioblastoma multiforme
• •* Focal disease
• •* Progressive or recurrent disease after prior treatment with radiotherapy and/or chemotherapy
• •* Low-grade astrocytoma that progressed to glioblastoma multiforme after prior radiotherapy and/or chemotherapy allowed
• •Gross tumor volume 5-60 mL
• •No intraventricular tumor, infratentorial tumor, or tumor that communicates with the ventricles
• •No bilateral non-contiguous gadolinium-enhancing tumor
• •No diffuse disease, defined as any satellite lesion \> 1.5 cm from the anticipated location of a catheter tip OR \> 2 satellite lesions
• •No ventricular invasion outside the anticipated radiotherapy volume
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •Karnofsky 60-100%
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Absolute neutrophil count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hemoglobin ≥ 9.0 g/dL
• •Hepatic
• •Bilirubin ≤ 1.5 mg/dL
• •AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• •Hepatitis B negative
• •No evidence of active hepatitis
• •Renal
• •Creatinine ≤ 1.7 mg/dL
• •BUN ≤ 2 times ULN
• •Cardiovascular
• •No uncontrolled hypertension
• •No unstable angina pectoris
• •No uncontrolled cardiac dysrhythmia
• •Other
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •Able to undergo MRI
• •Mini Mental State Exam score ≥ 15
• •No serious infection
• •No other medical illness that would preclude study participation
• •No other malignancy within the past 5 years except curatively treated carcinoma in situ or basal cell skin cancer
• •No psychological or sociological condition, addictive disorder, or other condition that would preclude study compliance
• •No known or suspected allergy to study drug or iodine
• •No known HIV positivity
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •No prior monoclonal antibodies
• •No prior local immunotherapy or treatment with the following biologic agents:
• •* Immunotoxins
• •* Immunoconjugates
• •* Antiangiogenesis compounds
• •* Antisense agents
• •* Peptide receptor antagonist
• •* Interferons
• •* Interleukins
• •* Tumor infiltrating lymphocytes
• •* Lymphokine-activated killer cells
• •* Gene therapy
• •Chemotherapy
• •See Disease Characteristics
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)
• •At least 3 months since prior polifeprosan 20 with carmustine implant (Gliadel wafer\^® )
• •Endocrine therapy
• •Must be maintained on a stable corticosteroid dose (approximately 4 mg) for ≥ 2 weeks before study entry
• •Radiotherapy
• •See Disease Characteristics
• •At least 3 months since prior radiotherapy
• •No prior brachytherapy or radiosurgery
• •Surgery
• •At least 4 weeks since prior surgery
• •Other
• •Recovered from all prior therapy
• •At least 1 month since prior investigational agents
• •No more than 2 prior treatment regimens
• •No other prior local therapy